Drugmaker Pulls Third-Line PARP Inhibitor Approval in Ovarian Cancer

(MedPage Today) -- Clovis Oncology has voluntarily withdrawn the indication for rucaparib (Rubraca) as a third-line treatment in BRCA-mutated ovarian cancer after an overall survival (OS) analysis showed a signal for potential harm, according to...